Insurance for QNatal® Advanced

A woman checks information on her phone
QNatal® Advanced noninvasive prenatal screening is covered by many insurance plans. When covered, 60% of patients pay $0. Learn more about the financial options available to your patients.

Smart codes for smart screening

Female doctors talking

Patients coming to your office for cervical cancer screening may also be at risk for sexually transmitted infections (STIs).

Quest Smart Codes make it easy to order both the cervical cancer screening and STI tests that cover your patients’ needs.

Smart Codes follow current screening guidelines (ACOG, CDC).

Protect their health

Group of young people against wall

Female patients under the age of 25 are most at risk for chlamydia and gonorrhea. Implement a universal screening program and protect their reproductive health with help from It’s Best to Test

Delivering clarity at every stage of their lives

Make sure your female patients get the testing they need at every stage of their lives.

The power of next-generation sequencing


QHerit™ combines next-generation sequencing (NGS) with a growing genomics database and includes tests recommended by guidelines and advocacy groups.


Co-testing recommended for women 30-65

Female doctor showing results to female patient

Co-testing solutions with Pap and HPV together for superior detection of risk versus either test alone.1,3


Test Interpretation Guides

Physician working at computer

See our guides for details on test selection, utilization, and interpretation. All information is based on peer-reviewed publications and practice guidelines.


  1. Kaufman HW, Alagia DP, Chen Z, Onisko A, Austin RM. Contributions of liquid-based (Papanicolaou) cytology and human papillomavirus testing in co-testing for detection of cervical cancer and precancer in the United States. Am J Clin Pathol. Published online ahead of print. July 8, 2020. doi:10.1093/ajcp/aqaa074
  2. Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol. 2015;123:282-288. doi:10.1002/cncy.21544
  3. Quest Diagnostics. Data on file. 2015